China: China Solicits Comments On Drug GCP

Last Updated: 21 December 2016
Article by Katherine Wang

The China Food and Drug Administration (“CFDA”) recently proposed revisions to the Good Clinical Practices for Pharmaceuticals (“GCP”), the most comprehensive revision in 13 years. The revisions (“Revisions”) are now open to public comments until January 31, 2017.

It’s notable that the Revisions have rewritten all the articles of the current GCP, but these sweeping changes are not especially innovative, as most of the concepts and principles have already been addressed in the International Conference on Harmonisation (“ICH”) GCP.

Overall, the Revisions set forth general principles of conducting clinical studies in China, as well as guidance of roles and responsibilities for the ethics committee (“EC”), the investigator and the sponsor, as well as the requirements for protocol and investigator’s brochure (“IB”). Highlights of the changes proposed in the Revisions are as follows:

  • Regulate the Handling and Retention of Biological Specimens: According to the Revisions, the sponsor shall be prohibited from conducting any testing that is unrelated to the study protocol approved by the EC on biological specimens. Additionally, the Revisions would require the sponsor to seek written consent from the subjects regarding the continuous storage of and/or possible use in any future research of leftover biological specimens after completion of the trial. The consent form would have to specify issues such as the retention period, the data confidentiality requirements, and the circumstances under which the data and specimens could be shared with other investigators.
  • Extend Insurance Coverage to Institutions: Unlike the current GCP, the Revisions would require the sponsor to insure or indemnify both the investigator and the institution against all claims, except for those arising from malpractice.
  • Allow an Individual to Serve as Sponsor or CRO: As a response to the pilot program of marketing authorization holder promulgated by the State Council this past June, the Revisions would allow individuals to act as sponsors and contract research organizations (“CROs”).
  • Specify the Requirement and Quantity of Retention Samples: Under the Revisions, reserve samples of study drugs for bioequivalence and bioavailability testing must be retained at the study site for no less than two years after marketing approval. The investigator will randomly select the reserve samples from the supply sent by the sponsor and should retain enough to allow five rounds of quality standard testing.
  • Detail the Process of Seeking Informed Consent from Subjects: Under the Revisions, the EC would have to pre-approve any new information that may affect subjects’ willingness to participate in the study. Importantly, the Revisions would prohibit agreements (whether oral or written) that ask subjects to waive their legal rights, or that may release the investigator, the institution, the sponsor, or its agents from liability.
  • Add Notification Requirement of the Unblinding Results: The Revisions propose that, for any double-blinding studies, the sponsor must provide the investigator and all study participants with the treatment allocation status after unblinding.
  • Revise the Data Retention Requirement: Whilst the current GCP imposes different data retention requirements on the investigator (e.g., five years after the study ends) and the sponsor (e.g., five years after obtaining marketing approval), the Revisions would impose similar obligations on both: data would have to be retained for two years after marketing approval or for five years after the study ends.
  • Require to Specify Direct Access to Source Records: The Revisions would require that under either the protocol or the clinical trial agreement ("CTA”), the investigator and the institution must be required to give the monitors and auditors direct access to the source data and source documents related to the clinical trial. This change may help clarify the industry’s concern regarding who may have access to subjects’ medical records to verify the authenticity of the study data, especially for the clinical trial data inspection campaign.
  • Clarify Contractual Arrangements Regarding CTA: The Revisions clearly stipulate that a CTA shall be structured as a three-party agreement between the sponsor, the investigator and the institution. Each party shall sign the CTA on his/her own capacity. In addition, for multi-center trials, the Revisions specify that the sponsor shall sign the CTA with all participating investigators and the relevant institutions.
  • Impose Regular Review Requirement of IB: The requirement regarding the IB in the current GCP is simple and general. The Revisions would incorporate the same detailed regulatory requirement on IB as that provided in the ICH GCP. In particular, according to the Revisions the sponsor must establish a written procedure regarding amendments to the IB, noting that the IB needs to undergo a review and amendment at least once per year. In addition, the Revisions add several provisions to set forth the purpose, general considerations, and contents regarding the IB.
  • Adopt Some Changes Reflected in the Latest ICH GCP: The latest version of the ICH GCP, the E6 (R2), was adopted by the ICH on November 9, 2016. Accordingly, the Revisions include a number of the new changes reflected in the E6 (R2), such as the notions of certified copies and validation of computerized systems, as well as the sections regarding quality management, risk management, oversight of CROs, and risk-based monitoring, among others. To some extent, it reflects CFDA’s willingness to establish a regulatory framework in line with international standards.

The Revisions would standardize the conduct of drug studies in China, as well as strengthen the management of such studies. It remains unclear whether and when these changes will be adopted. We recommend that pharmaceutical companies closely monitor the progress of the Revisions and propose their comments by the deadline.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions